Eliglustat
 | |
| Clinical data | |
|---|---|
| Trade names | Cerdelga |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H36N2O4 |
| Molar mass | 404.543 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Eliglustat (INN, USAN;[1] trade name Cerdelga) is a treatment for Gaucher's disease developed by Genzyme Corp that was approved by the FDA August 2014.[2] Commonly used as the tartrate salt, the compound is believed to work by inhibition of glucosylceramide synthase.[3][4] According to an article in Journal of the American Medical Association the oral substrate reduction therapy resulted in "significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count" in untreated adults with Gaucher disease Type 1.[5]
Cost
In 2014, the annual cost of eliglustat taken orally twice a day was $310,250. Genzyme's flagship imiglucerase (brand name Cerezyme) cost about $300,000 for the infusions if taken twice a month.[6] Manufacturing costs for eliglustat are slightly lower than for imiglucerase. Genzyme's maintains higher prices for orphan drugs —most often paid for by insurers— in order to remain financially sustainable.[6]
References
- ^ Eligustat (PDF), AMA By subscription only
- ^ FDA approves new drug to treat a form of Gaucher disease, U.S. Food and Drug Administration, 19 August 2015, retrieved 18 July 2015
- ^ Lee, L.; Abe, A.; Shayman, J. A. (21 May 1999). "Improved Inhibitors of Glucosylceramide Synthase". Journal of Biological Chemistry. 274 (21): 14662–14669. doi:10.1074/jbc.274.21.14662.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Shayman, JA (1 August 2010). "Eliglustat Tartrate: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease". Drugs of the future. 35 (8): 613–620. PMID 22563139.
- ^ "Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial", Journal of the American Medical Association, 313 (7): 695–706, 17 February 2015, doi:10.1001/jama.2015.459
{{citation}}: Cite uses deprecated parameter|authors=(help) - ^ a b Robert Weisman (2 September 2014), New Genzyme pill will cost patients $310,250 a year, The Boston Globe, retrieved 18 July 2015
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |